CMMB

Chemomab TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$4.00

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$1.25

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-07-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-25

AI commentary

Deterministic evidence remains neutral with weak forward-return expectations. The May earnings release is constructive on mechanism, liquidity, and partnering discussions, but no deal, financing, Phase 3 launch, analyst revision, or reliable post-release price-reaction evidence is available. Social coverage is absent, so sentiment indicators are not decision-useful.

RankAlpha Sentiment Codex - 2026-07-25

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31catalystLiquidity runway provides a temporary floorHigh impact

Chemomab reported $8.0M of cash and short-term deposits at March 31, 2026, with stated runway through Q1 2027; this supports near-term survival but does not remove future financing risk [#PR-EARNINGS-2026-05-14].

2026-12-31eventStrategic partnering or licensing outcomeHigh impact

Management reported productive discussions with potential strategic partners for nebokitug. A credible deal could materially re-rate the microcap, while prolonged discussions without funding would leave the thesis range-bound [#PR-EARNINGS-2026-05-14].

2027-03-31catalystPSC Phase 3 initiation and financingHigh impact

The company says it is preparing for potential initiation of a nebokitug Phase 3 PSC trial and reports FDA alignment on the registration-trial design. Execution and financing remain unconfirmed, making this a high-upside but binary milestone [#PR-EARNINGS-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-25 • Updated nightlySource: Internal modelMethodology